Reports Q3 revenue $5.51B, consensus $5.49B. “We increased our organic growth trajectory in Q3 while delivering strong margin and EPS growth fueled by BD Excellence, enabling us to raise our EPS guidance and reaffirm organic revenue growth expectations for the full year,” said Tom Polen, chairman, CEO and president of BD. “We also announced in July an agreement to combine BD’s Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to create an innovative life science and diagnostic leader focused on high-volume testing with a leading financial outlook. We are focused on closing the transaction and realizing the meaningful value-creation opportunity for BD shareholders through capturing the upside of synergies and growth within the combined company as well as maximizing the value of New BD. Looking ahead for the remainder of the fiscal year, we remain focused on further accelerating sequential growth as we position New BD for its next chapter of long-term success.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Notable companies reporting before tomorrow’s open
- BDX Earnings this Week: How Will it Perform?
- Becton Dickinson to invest $35M to expand prefilled flush syringe manufacturing
- Becton Dickinson receives FDA clearance for BD Veritor System for SARS-CoV-2
- Becton Dickinson, BNY, Incyte, Duolingo, Jabil: Major Stock Sales Unveiled!